Compare Freshworks Inc (FRSH) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Natera Inc. Common Stock — how do they compare? Freshworks Inc trades at $13.69 (market cap $3.57B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 16× Freshworks Inc's market cap, and Freshworks Inc is more actively traded (4,701,335 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 40 Days and Natera Inc. Common Stock for 0 Days on average.
| FRSH | NTRA | |
|---|---|---|
Market Cap | $3.57B | $57.03B |
Volume | 4,701,335 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $13.92 | $425.64 |
52-Week Low | $6.88 | $179.42 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $2.94B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.90, down 0.14% with a bullish technical outlook. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains strong at 16% YoY, with improving margins and positive cash flow trends. Analyst consensus is evenly split between Buy and Hold ratings with a $14.60 price target.
FRSH presents a compelling growth story with accelerating profitability and AI-driven product expansion. Key risks include competitive pressures in the SaaS sector and execution challenges in enterprise market penetration. The stock's current valuation at 22x P/E appears reasonable given the company's growth trajectory and improving financial metrics.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
